Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Rhea-AI Summary

Decoy Therapeutics (Nasdaq:DCOY) announced that CEO Rick Pierce will speak at hVIVO’s Capital Markets Day on June 11, 2026, in London. He will discuss early clinical development, the role of human challenge trials, and Decoy’s AI-enabled D-MAV antiviral pipeline, which is aiming for first clinical entry in 2027.

News Market Reaction – DCOY

-5.45%

5 alerts

-5.45% Session close to close

+15.3% Peak Tracked

-16.6% Trough Tracked

$3.72M Market Cap

0.5x Rel. Volume

In the Jun 8 session, DCOY declined 5.45%, reflecting a notable negative market reaction. Argus tracked a peak move of +15.3% during that session. Argus tracked a trough of -16.6% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.5% in the session following this news. A negative reaction despite constructive v...

Analysis

The stock moved -5.5% in the session following this news. A negative reaction despite constructive visibility would fit prior patterns where positive-sounding updates on June 1 and 3 were followed by declines of -6.28% and -7.43%. Participation in a capital markets event extends the existing hVIVO relationship and reinforces messaging around an anticipated 2027 clinic entry, but such soft catalysts have previously struggled to offset broader concerns reflected in a share price 60.93% below the 52-week high.

Key Figures

Event date: June 11, 2026 Clinic target year: 2027

2 metrics

Event date June 11, 2026 CEO speaking at hVIVO Capital Markets Day in London

Clinic target year 2027 D-MAV pipeline targeting entry into the clinic

Historical Context

5 past events · Latest: 2026-06-03 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
2026-06-03	Board nomination	Positive	-7.4%	Nomination of experienced global biopharma executive to the board.
2026-06-01	Strategic partnership	Positive	-6.3%	Strategic collaboration with hVIVO to advance lead D-MAV into trials.
2026-05-26	Advisory appointment	Positive	+4.5%	MIT professor and co-founder named Chair of Scientific Advisory Board.
2026-04-27	Conference presentations	Positive	+1.6%	Presentations at peptide therapeutics conferences with new preclinical data.
2026-04-09	Pipeline update	Positive	+6.6%	Update on accelerated execution and clearly defined path to clinic.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent company news has often been positive in tone but has produced mixed reactions, with several strategic or partnership updates followed by negative price moves.

Recent Company History

Over the past few months, Decoy Therapeutics announced multiple strategy and visibility milestones. Governance and scientific depth were strengthened with board and advisory appointments on 2026-05-26 and 2026-06-03. A key step was the 2026-06-01 collaboration with hVIVO to move its lead D-MAV candidate toward Phase 1 and 2a studies. Earlier, presentations and a broader clinical development update in April signaled accelerating execution. Against this backdrop, the CEO’s participation in hVIVO’s Capital Markets Day extends the ongoing partnership and capital-markets engagement trend.

Key Terms

designable multi-antivirals, human challenge trials, human challenge models, pan-coronavirus, +1 more

5 terms

designable multi-antivirals medical

"a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category"

Engineered antiviral medicines created with flexible design platforms so a single drug or family of drugs can target multiple viruses or several steps in a virus’s life cycle. Think of them like a multi-tool or a universal key that can be adapted to different locks; for investors they matter because one successful platform can address many diseases, potentially shortening development time, spreading commercial risk across more products, and increasing market opportunity — while still requiring clinical proof and regulatory approval.

human challenge trials medical

"strategic value of human challenge trials in moving novel therapeutics toward the clinic"

Human challenge trials are clinical studies in which healthy volunteers are intentionally exposed to a pathogen under controlled conditions to test a vaccine or treatment. For investors, they matter because they can produce faster, more direct evidence of whether a product works, like testing a lock by trying the key, but they also carry higher ethical, safety and regulatory scrutiny that can speed up or complicate development timelines and public perception.

human challenge models medical

""Human challenge models are one of the tools that can shorten that path""

Human challenge models are research studies in which carefully screened volunteers are deliberately exposed to a virus, bacteria or a controlled dose of an experimental treatment so scientists can observe how disease develops and whether a vaccine or drug works. For investors, these studies can speed up development and cut costs by providing early evidence of effectiveness or safety, but they also carry ethical and regulatory risks—think of testing a new car on a closed track versus in everyday traffic.

pan-coronavirus medical

"Led by a pan-coronavirus program, the pipeline is targeting the clinic in 2027."

Pan-coronavirus describes medicines, vaccines or diagnostic tools designed to work against a broad range of coronaviruses and their variants by targeting features those viruses share. For investors, a pan-coronavirus product is like a universal charger: one solution can serve many future outbreaks and strains, which can expand the potential market, reduce the risk that a single new variant will make the product obsolete, and therefore affect a developer’s long-term revenue and valuation.

ai-enabled imp³act platform technical

"built on its AI-enabled IMP³ACT platform, designed to shorten the path from concept"

An AI-enabled imp³act platform is a software system that uses artificial intelligence to measure, manage and optimize social or environmental outcomes alongside financial performance. For investors it acts like a smart dashboard and advisor combined—automating data collection, spotting trends or risks, and guiding where capital can achieve measurable impact—so stakeholders can compare projects, track progress, and make decisions with clearer evidence of both returns and real-world effects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

CAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer Rick Pierce will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on June 11, 2026 in Canary Wharf, London.

The half-day event brings together analysts, institutional investors and media to examine how specialist partners support faster, better-informed decisions in early drug development, including the strategic value of human challenge trials in moving novel therapeutics toward the clinic.

Decoy is advancing a pipeline of D-MAVs built on its AI-enabled IMP³ACT platform, designed to shorten the path from concept to clinic. Led by a pan-coronavirus program, the pipeline is targeting the clinic in 2027.

"The companies that reach patients fastest are usually the ones that choose the right development partners early," said Pierce. "Human challenge models are one of the tools that can shorten that path, and that aligns closely with how we are building Decoy. I'm looking forward to a candid discussion about what it takes to develop a new class of antivirals at speed."

Attendance is limited; analysts, investors and media can register interest at hVIVO@icrhealthcare.com, and a recording will be posted to hVIVO's website after the event.

About Decoy Therapeutics

Decoy Therapeutics is a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs), a new category of antivirals engineered to target shared viral mechanisms, enabling a single, adaptable drug to work across multiple viruses. Built on the proprietary IMP³ACT platform, which combines AI-assisted design and rapid synthesis, Decoy develops peptide antivirals designed to move faster into the clinic and expand what is possible in viral prevention and treatment. The company's lead candidates target multiple respiratory viruses, addressing the health and societal burden of viral disease.

Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "can," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP³ACT^™ platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy's actual results may vary materially from those expected or projected.

View original content to download multimedia:https://www.prnewswire.com/news-releases/decoy-therapeutics-ceo-to-participate-in-hvivo-capital-markets-day-in-london-302793469.html

SOURCE Decoy Therapeutics, Inc

FAQ

When and where will Decoy Therapeutics (DCOY) CEO speak at the hVIVO Capital Markets Day 2026?

Rick Pierce, CEO of Decoy Therapeutics (DCOY), is scheduled to speak on June 11, 2026, in Canary Wharf, London. According to Decoy Therapeutics, the half-day hVIVO Capital Markets Day targets analysts, institutional investors, and media interested in early drug development and human challenge trials.

What topics will Decoy Therapeutics (DCOY) cover at the hVIVO Capital Markets Day in London?

Rick Pierce plans to discuss early clinical development and how specialist partners and human challenge models support faster decisions. According to Decoy Therapeutics, the discussion will also highlight the company’s approach to building Designable Multi-Antivirals (D-MAVs) and advancing novel antivirals toward the clinic using its AI-enabled IMP³ACT platform.

Why is Decoy Therapeutics (DCOY) participating in the hVIVO Capital Markets Day important for investors?

Participation showcases Decoy Therapeutics’ positioning in early clinical development and human challenge models. According to Decoy Therapeutics, the event highlights its D-MAV pipeline strategy, relationships with specialist partners, and plans for moving its pan-coronavirus and other programs toward first-in-human clinical trials targeted for 2027, which may interest long-term investors.

What is Decoy Therapeutics’ D-MAV pipeline and clinic timeline highlighted at hVIVO’s 2026 event?

Decoy Therapeutics is developing Designable Multi-Antivirals (D-MAVs) targeting shared viral mechanisms across virus families. According to Decoy Therapeutics, its pipeline, led by a pan-coronavirus program and built on the AI-enabled IMP³ACT platform, is targeting initial clinical entry in 2027, aiming to shorten the concept-to-clinic development path.

How can analysts and investors attend or watch Decoy Therapeutics’ session at hVIVO Capital Markets Day 2026?

Attendance at the hVIVO Capital Markets Day is limited and requires registering interest via hVIVO@icrhealthcare.com. According to Decoy Therapeutics, a recording of the event will be posted on hVIVO’s website after the session, offering analysts, investors, and media later access to the discussion.

Who will join Decoy Therapeutics (DCOY) CEO on the hVIVO Capital Markets Day 2026 panel?

Rick Pierce will speak alongside representatives from Boehringer Ingelheim, RA Capital, and ILiAD Biotechnologies. According to Decoy Therapeutics, this group of specialist partners will focus on how collaborations and human challenge trials can support faster, better-informed decisions in early drug development and advancement of novel antiviral therapeutics.